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Abstract
Background: Tau abnormal hyperphosphorylation and the formation of neurofibrillary tangles in AD brain is the
result of upregulation of tau kinases and downregulation of tau phosphatases.
Methods: In a group of 729 Spanish late-onset Alzheimer’s disease (AD) patients and 670 healthy controls, we
examined variations into a set of candidate genes (PPP2CA, PPP2R2A, ANP32A, LCMT1, PPME1 and PIN1) in the tau
protein phosphatase-2A (PP2A) pathway, to address hypotheses of genetic variation that might influence AD risk.
Results: There were no differences in the genotypic, allelic or haplotypic distributions between cases and controls
in the overall analysis or after stratification by age, gender or APOE ε4 allele.
Conclusion: Our negative findings in the Spanish population argue against the hypothesis that genetic variation in
the tau protein phosphatase-2A (PP2A) pathway is causally related to AD risk
Background
One of the neuropathological hallmarks in Alzheimer’s
disease (AD) is neurofibrillary tangles (NFTs), which are
composed of the microtubule-binding protein tau that is
hyperphosphorylated [1]. Tau phosphorylation is catalysed
by tau protein kinases and reversed by tau protein phos-
phatases [2]. It has been reported that the expression and
activity of the major tau phosphatase in human brain, pro-
tein phosphatase-2A (PP2A), is decreased in the affected
areas of AD brain [3,4], suggesting that a downregulation
of tau phosphatases in AD brain might underlie the abnor-
mal hyperphosphorylation of tau. The overall PP2A activ-
ity is determined by composition of the holoenzyme from
the catalytic subunit alpha (PP2CA) and the regulatory
subunit B alpha (PP2R2A), the level of PP2A inhibitors
such as ANP32A (inhibitor-1 of protein phosphatase-2A),
and changes in PP2A methylation regulated by the leucine
carboxyl methytransferase-1 (LCMT1) and the protein
phosphatase methylesterase-1 (PPME1); in addition, the
peptidyl-prolyl cis/trans isomerase PIN1 induces confor-
mational changes in tau that can facilitate tau dephosphor-
ylation by PP2A (Figure 1). Consequently, PPP2CA,
PPP2R2A, ANP32A, LCMT1, PPME1 and PIN1 are good
candidate genes for the analysis of AD susceptibility. The
largest genome wide association (GWA) study in AD [5]
did not find significant results for all these PP2A-related
genes. However, it cannot be discarded that these genes in
the tau PP2A pathway are among the genes with signifi-
cant nominal association but without reaching significance
(p < 10
-5 or less) after adjustment for multiple testing in
GWAs; in addition, it is also possible that some of the
SNPs analyzed in our study were not present in the arrays
used in GWAs. Therefore, we conducted a case-control
association study involving genes in the tau PP2A pathway
in relation to AD risk, in a Spanish cohort.
Methods
The study included 729 AD patients (67% women; mean
age at study 77.2 years; SD 8.0; range 61-103 years;
mean age at onset 73.3 years; SD 7.8; range 60-100
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AD [6]. All AD cases were defined as sporadic because
their family history did not mention any first-degree
relative with dementia. AD patients were recruited from
the Departments of Neurology of University Hospital
“Marqués de Valdecilla” (Santander, Spain) and Hospital
“La Paz” (Madrid, Spain), and from Alzheimer Center
Reina Sofia Foundation (Madrid, Spain). The large
majority of patients were living in the community and
had been referred by their general practitioner; few had
been admitted from hospital wards or nursing home
facilities. Control subjects were 670 unrelated indivi-
duals (64% women; mean age 78.3 years; SD 9.4; range
60-104 years) randomly selected from nursing homes.
These subjects had complete neurologic and medical
examinations that showed that they were free of signifi-
cant illness and had Mini Mental State Examination
scores of 28 or more, which were verified by at least
one subsequent annual following-up assessment. The
controls arose from the same base population as the
cases. The AD and control samples were Caucasians ori-
ginating from a limited geographical area in northern
Spain (Santander) and from the central area of Spain
(Madrid).
Blood samples were taken after written informed con-
sent had been obtained from the subjects or their repre-
sentatives. The study was approved by the ethical
committees of the University Hospital “Marqués de Val-
decilla”, Alzheimer Center Reina Sofia Foundation, and
the Hospital “La Paz”. Genotyping of PPP2CA
(rs7705319 and rs4958177), PPP2R2A (rs2046225,
rs7823021, rs17055172, rs12676426 and rs2046223),
ANP32A (rs2924633, rs1551345, rs1551344, rs1551342,
rs11632936, rs2958405 and rs1551343), LCMT1
(rs8062337, rs277898, rs277886 and rs277892), PPME1
(rs10898966, rs2848557, rs500608 and rs544356), and
PIN1 (rs2233678, rs1077220, rs2010457 and rs2287838)
polymorphisms was performed using the iPLEX Gold
assay on the MassArray system (Sequenom Inc., San
Diego, USA). We used data from the HapMap project
http://www.hapmap.org to select htSNPs capturing
100% of PPP2CA genetic variability, 75% of PPP2R2A,
95% of ANP32A, 95% of LCMT1, 75% of PPME1, and
80% of PIN1 genetic variability in Caucasians. SNPs
were chosen among those with minor allele frequencies
≥ 5% using Haploview v3.2 software http://www.broad.
mit.edu/mpg/haploview with an r
2 threshold of 0.8.
PPP2R2A rs12676426 and PPME1 rs500608 that were
significantly deviated from Hardy-Weinberg equilibrium
(HWE) were excluded from the analysis. In addition, we
removed PIN1 rs1077220 with a non-homogeneous gen-
otypic distribution between our two control populations
(Santander and Madrid) and which were also different
from the HapMap CEU distribution.
HWE was calculated for the htSNPs in the control
population using Pearson’s c
2 statistics. We assessed
pairwise linkage disequilibrium (LD) between the
htSNPs by D’ and r
2 statistics. Haplotype reconstruc-
tion and their frequencies in cases and controls were
estimated by an expectation-maximization algorithm,
method implemented in Haploview 3.32. Pearson’s c
2
statistics were performed to compare genotype, allele,
and haplotype distribution of the patients and control
for each htSNP. Genotypic and allelic distributions
were assessed by logistic regression using SPSS
software.
Results
As shown in Table 1, the distribution of the minor allele
frequencies of the PP2A-related genes did not differ sig-
nificantly between AD and control groups. Haplotype
distributions were not significantly different between
cases and controls in the overall analysis or after stratifi-
cation by APOE ε4 allele (data not shown). There were
no major differences in allele, genotype or haplotype fre-
quencies in our total sample associated to either age or
gender subgroups. The data set was analyzed for epi-
static interactions between the 6 PP2A-related genes
and no significant effects were observed.
Discussion
Genes harbouring markers with only modest evidence
of association (nominally significant but not reaching
the genome-wide significance threshold) can be identi-
fied if they belong to the same biological pathway or
mechanism; therefore, pathway-based approaches,
Figure 1 Genes related with the tau protein phosphatase-2A
(PP2A) pathway. PP2A dephosphorylates tau and is composed of
an structural subunit A, a catalytic subunit alpha (PPP2CA) and a
regulatory subunit B alpha (PPP2R2A). The peptidyl-prolyl cis/trans
isomerase PIN1 binds to tau and facilitates PP2A activity, whereas
ANP32A inhibits PP2A activity. Methylation by the leucine carboxyl
methyltransferase-1 (LCMT1) increases PP2A activity, and
demethylation by protein phosphatase methylesterase-1 (PPME1)
reduces PP2A activity.
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or related genes, might complement the most-signifi-
cant SNPs/genes approach for interpreting genome-
wide association (GWA) data on complex diseases
[7,8]. In fact, genetic variation in the immune system
and in lipid metabolism pathways is a cause of AD
susceptibility [9,10]. Although genetic markers of the
genes examined in this study (PPP2CA, PPP2R2A,
ANP32A, LCMT1, PPME1 and PIN1) were not found
associated to AD in the largest GWA study [5], our
main hypothesis was that common variation in genes
directly related to tau dephosphorylation in the PP2A
pathway might underlie individual differences in sus-
ceptibility to AD. To our knowledge, this study is the
first of its type to be conducted in this pathway. There
is a selective and significant neuron-specific reduction
in PP2A catalytic subunit and PP2A regulatory B subu-
nit mRNAs in AD hippocampus [3,4], and this reduced
neuronal PP2A immunoreactivity closely correlates
with NFT load [4], suggesting that PP2A dysfunction
c o n t r i b u t e st oA Dt a up a t h ology. In addition, cDNA
microarray techniques have revealed downregulated
expression of PPP2CA gene in AD brain [11,12]. Con-
versely, in AD brain has been observed a significant
increase in the neocortical levels of PP2A inhibitors
[13], which co-localize with abnormally hyperpho-
sphorylated tau. These data suggest the possible invol-
vement of ANP32A (inhibitor-1 of PP2A) in AD
neurofibrillary pathology through the inhibition of
PP2A activity. LCMT1 promotes PP2A activity by
methylating its catalytic subunit, and PPME1 catalyses
the removal of the methyl group, thus reversing the
activity of LCMT1. Methylated PP2A catalytic subunit
levels are reduced in AD frontal/temporal cortex [14],
and LCMT1 levels are also selectively decreased in
AD-affected regions and in tangle-bearing neurons
[15]. An interaction between tau and PIN1 is thought
to facilitate the dephosphorylation of hyperphosphory-
lated tau by PP2A, promoting microtubule stability
[ 1 6 ] .I nA Db r a i n ,P I N 1e x p r e s s i o ni nt h eh i p p o c a m -
pus and parietal cortex is low [17] and inversely corre-
lated with neurofibrillary degeneration [18].
In an Italian study [19], carriers of PIN1 (-842,
rs2233678) C allele had an increased risk of AD, lower
age of onset, and reduced PIN1 levels in peripheral
mononuclear cells, but subsequent studies [20-23] did
not replicate these findings. We failed to detect the
association of PIN1 (-842, rs2233678) with AD. We
also failed to observe any allele, genotype or haplotype
association of PPP2CA, PPP2R2A, ANP32A, LCMT1
and PPME1 genes with AD. Because we studied
h t S N P sc a p t u r i n g8 0 %o fP I N 1a n d7 5 %o fP P P 2 R 2 A
and PPME1 genetic variability, it might be argued that
we have missed a hypothetical disease locus, which
would have been detected by analysis of extended hap-
lotypes; however, the complete linkage disequilibrium
across the PIN1, PPP2R2A and PPME1 regions in our
study argues against this possibility. Our negative
results with all these PP2A pathway-related genes are
probably not due to insufficient statistical power,
because our sample size had enough power (94%) to
detect and odds ratio of 1.5 at disease allele frequen-
cies of 0.10.
Conclusion
Despite supporting evidence for the biological role of
tau phosphatases in AD exists, our negative findings in
the Spanish population argue against the hypothesis that
Table 1 Minor allele frequencies distribution of tau phosphatases genes in AD patients and controls
Gene SNP MAF, AD/C P-value Gene SNP MAF, AD/C P-value
PPP2CA rs7705319 0.20/0.20 0.99 LCMT1 rs8062337 0.32/0.30 0.34
rs4958177 0.11/0.10 0.46 rs277898 0.37/0.38 0.35
rs277886 0.34/0.32 0.16
PPP2R2A rs2046225 0.38/0.37 0.49 rs277892 0.28/0.27 0.40
rs7823021 0.28/0.29 0.88
rs17055172 0.15/0.17 0.31 PPME1 rs10898966 0.11/0.09 0.24
rs2046223 0.38/0.39 0.82 rs2848557 0.34/0.34 0.84
rs544356 0.20/0.20 0.89
ANP32A rs2924633 0.40/0.40 0.67
rs1551345 0.09/0.08 0.48 PIN1 rs2233678 0.11/0.12 0.47
rs1551344 0.07/0.06 0.31 rs2010457 0.33/0.32 0.83
rs1551342 0.11/0.12 0.57 rs2287838 0.48/0.49 0.84
rs11632936 0.27/0.27 0.97
rs2958405 0.31/0.34 0.07
rs1551343 0.13/0.11 0.20
P -values not corrected for multiple comparisons.
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